Filing Flows

Filing Flows › Companies › Biotricity › Cash flow

Biotricity cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow$507K in Q1 FY27 · $162K over twelve months

Operating cash flow$507K
Free cash flow+$507K
Cash conversion cycle-889 days

Analysis

In Q1 FY27, Biotricity generated $507K of operating cash flow. That is $881K more than in Q1 FY26 (−$373K).

Over the twelve months to Jun 30, 2026, operating cash flow was $162K; the largest uses were other financing ($69K); the cash balance rose by $75K.

Operating cash flow was $507K against net income of −$959K. The largest differences: receivables +$573K, stock-based pay +$340K, inventory −$84K.

Its cash conversion cycle was -889 days (receivables 57 + inventory 169 − payables 1114): suppliers fund its working capital.

Free cash flow

Biotricity: free cash flow by quarterBiotricity: free cash flow by quarter−$397KQ2 FY25−$88KQ3 FY25−$401KQ4 FY25−$373KQ1 FY26$416KQ2 FY26−$740KQ3 FY26−$21KQ4 FY26$507KQ1 FY27
Operating cash flow less capital spending.
Biotricity: operating cash flow against capital spendingBiotricity: operating cash flow against capital spendingOperating cash flowCapital spending−$397K$0Q2 FY25−$88K$0Q3 FY25−$401K$0Q4 FY25−$373K$0Q1 FY26$416K$0Q2 FY26−$740K$0Q3 FY26−$21K$0Q4 FY26$507K$0Q1 FY27
Latest (Q1 FY27): Operating cash flow $507K, Capital spending $0.

Capital allocation, year by year

Biotricity: where the cash came from (up) and went (down), by fiscal yearBiotricity: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY22: Operating cash flow −$15.2MFY22: Net borrowing $23.5MFY22: Shares issued $350KFY22: Capital spending −$30K$23.9MFY22FY23: Operating cash flow −$13.5MFY23: Net borrowing $2.4M$2.4MFY23FY24: Operating cash flow −$6.7MFY24: Net borrowing $3.0MFY24: Shares issued $2.9M$5.9MFY24FY25: Operating cash flow −$2.4MFY25: Shares issued $1.9M$1.9MFY25FY26: Operating cash flow −$719KFY26
Over these 5 years operating cash flow totalled −$38.5M; the largest uses were operating cash flow ($38.5M) and capital spending ($30K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$467K
Debt$1.1M
Net debt$683K

Biotricity funds itself: free cash flow was $162K over the last twelve months, and $467K of cash and investments stands against $1.1M of debt.

Where the cash came from and went

Biotricity: sources (+) and uses (−) of cash, Q1 FY27Biotricity: sources (+) and uses (−) of cash, Q1 FY27Operating cash flow$507KCash drawn (+) / kept (−)−$317KOther financing−$191KExchange rates$422
Biotricity: sources (+) and uses (−) of cash, TTM to Q1 FY27Biotricity: sources (+) and uses (−) of cash, TTM to Q1 FY27Operating cash flow$162KCash drawn (+) / kept (−)−$75KOther financing−$69KExchange rates−$18K

From profit to cash

Biotricity: net income to operating cash flow, Q1 FY27Biotricity: net income to operating cash flow, Q1 FY27Net income−$959KDepreciation & amortization$1KStock-based pay$340KReceivables$573KInventory−$84KPayables$80KOperating cash flow$507K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY27571691114-889
Q4 FY2648175925-702
Q3 FY26422641027-720
Q2 FY26472641030-719
Q1 FY2641201933-691
Q4 FY2535194998-769
Q3 FY2535182939-722
Q2 FY2542212977-722

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27$507K—−$317K$507K
Q4 FY26−$21K—$107K−$21K
Q3 FY26−$740K—$52K−$740K
Q2 FY26$416K—$83K$416K
Q1 FY26−$373K—−$26K−$373K
Q4 FY25−$401K$7−$9K−$401K
Q3 FY25−$88K−$1−$182K−$88K
Q2 FY25−$397K$420K−$73K−$397K

Biotricity: income statement and cash flow

Biotricity, Q1 FY27: revenue $4.3M (+10% year over year), operating margin 3.7%. The chart follows the revenue to costs, profit and cash.

Biotricity: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.